AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$WAT

Bernstein raises Waters stock price target to $535 on earnings beat

Bernstein raised its price target on Waters Corp. (WAT) to $535 from $450, citing strong Q3 2026 results. Revenue grew 10% in constant currency, and adjusted EPS of $4.10 beat estimates. The company raised full-year 2026 guidance for revenue and EPS. Bernstein described the 2027 outlook as conservative, with mid-single-digit-plus organic growth expected. Other analysts also raised price targets following the earnings beat.

Original reporting
investing.com
Published Nov 4, 2026, 2:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$WAT
Bullish
high confidence
Mentioned
$WAT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$WATBullishHigh
01

Why it matters

Earnings beat and raised guidance drove analyst upgrades, suggesting further upside.

02

Market read

The earnings beat and guidance lift are fresh primary disclosures that can move the stock and its sector.

03

What to watch

Potential headwinds from China demand and macro‑economic slowdown could temper upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Waters Corp. (NYSE:WAT) is a leading provider of analytical instruments; its Q3 2026 results were released on Tuesday.

Company-level read

Ticker impact

$WATBullishHigh confidence
Context

Waters Corp. reported Q3 2026 earnings beat and raised full-year guidance, prompting analysts to lift price targets.

Expected impact

likely upward pressure as the market prices in higher earnings and guidance

Evidence & confidence

The earnings beat and guidance lift are fresh primary disclosures; analysts have already increased targets, indicating bullish sentiment.

Market effects

Sector

Strengthens the analytical chemistry and life‑science tools sector outlook.

Regional

Positive for U.S. biotech and instrument makers.

Global

Modest, limited to sector peers.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock may face short‑term profit‑taking.

Key entities

  • Analyst
    Bernstein SocGen Group

    Raised price target to $535 and maintained Outperform rating.

  • Analyst
    KeyBanc

    Raised price target to $500, Overweight rating.

  • Analyst
    Stifel

    Raised price target to $470, citing strong Q3 performance.

Read at source← All news

StoryWaters Corp. posts Q3 2026 revenue of $1.767 B, raises full‑year guidance and announces MOBILion acquisition

Also covered by

4 outlets

Related articles

NOV 4
$WATMed

KeyBanc raises Waters stock price target to $500 on guidance boost

KeyBanc raised its price target for Waters Corp. (WAT) to $500 from $460, citing strong Q3 results and raised guidance. WAT reported 10% revenue growth and 30.1% adjusted operating margin, exceeding estimates. The stock is up 52% in six months, trading near $460. Stifel also raised its target to $470 but maintained a Hold rating. WAT's full-year guidance was increased to 9.1%-9.7% growth, with AI and China growth cited as positive factors.

investing.com2 min
NOV 4
$WATMedAI 8/10

Waters Q3 Earnings Call Highlights

Waters Corporation (WAT) reported Q3 revenue of $575M in Advanced Diagnostics, up 2%, and $500M in Diagnostic Solutions, flat. Microbiology revenue grew 4% outside China but declined 20% in China. Clinical Business Unit revenue rose 17%, and Materials Sciences revenue increased 7%. The company expects to recover revenue from reagent-rental compliance and announced partnerships for its Onclarity HPV kit.

finance.yahoo.com2 min